

Diagnosis of Diabetes				
ADA Diagnostic Criteria	A1C Correlation	on to Ave	erage Gluc	ose
1. A1C ≥ 6.5%ª			plasma	
OR	A1C (%)	giu mg/dL	cose mmol/L	
2. 8-hour FPG ≥ 126 mg/dL (7 mmol/L)	5	97	5.4	•
OR	6	126	7.0	
3. 2-hr plasma glucose ≥ 200 mg/dL (11.1 mmol/L)	7	154	8.6	
during OGTT	8	183	10.2	
OR	9	212	11.8	
4. Dandam plasma glucasa > 200 mg/dL /11.1	10	240	13.4	
4. Random plasma glucose ≥ 200 mg/dL (11.1	11	269	14.9	
mmol/L) with classic symptoms of hyperglycemia	12	298	16.5	
^a less reliable in increased red blood cell turnover such as sickle cell disease, hemodialysis, recent blood loss/transfusion, erythropoietin therapy, some HIV drugs, and iron-deficient anemia	Caveats	: RBC turnov	er, ethnicity	
CERIATRIC PHARMACIST OGTT, oral glucose tolerant test BOOT C MP ADA Standards of Care. Diabetes C	are. 2025;48(S1):S1-S282.			6

Glycem	ic Goals in Older Adult	s (ADA)		
Patient Characteristics/ Health Status	Rationale	Reasonable A1C goal	Pre-meal glucose mg/dL (mmol/L)	Bedtime glucose mg/dL (mmol/L)
Healthy (few chronic illnesses, intact cognitive/functional status)	Longer life expectancy	<7.0 - 7.5%	80-130 (5-7.2)	80-180 (5-8.3)
<u>Complex/intermediate</u> (multiple chronic illnesses or 2+ instrumental ADL impairments or mild-moderate cognitive impairment)	 Intermediate life expectancy > Treatment burden > Hypoglycemia and fall risk 	< 8.0%	90-150 (5-8.3)	100-180 (5.6-10)
Very complex/poor health (long-term care or end-stage chronic illness or mod-severe cognitive impairment or 2+ ADL dependencies)	Limited life expectancy	Avoid hypoglycemia & symptomatic hyperglycemia	100-180 (5.6-10)	110-200 (6.1-12.2)
End of Life	Goal is comfort	hy	cemia and sym perglycemia	


bps.


Diabetes Treatment Burden: Intensive Glucose Control


- Lifetime DM treatment, \downarrow A1C 1% QALY gained:
 - 45-year-old: ~1 QALY
 - 65-year-old: ~0.3 QALY
 - 75-year-old: ~0.1 QALY
- \uparrow burden negates benefit especially for those \geq 65 years
 - Common reported burden of insulin eliminates benefit


QALY, net quality-adjusted life-years—incorporates both the quantity and quality of life related to all the potential benefits and harms of therapy


GERIATRIC PHARMACIST BOOT C&MP ADA. Diabetes Care. 2025;48(51):51-5308; ACCE/ACE Guidelines available at: https://www.aace.com/publications/guidelines. Accessed 1/4/25























Μ	etfor	min					
Efficacy			CV Ef			al Effects	Additional Considerations
	glycemia	Change	MACE	HF	Progression of DKD	Dosing/Use Considerations	
High	No	Neutral	Potential Benefit	Neutral	Neutral	 CI when eGFR < 30 Caution and dose reduction when eGFR 30 - 45 	 GI SE common (N/D) Take with food Slow dose titration ER formulation Possible weight loss Potential for B12 Deficiency
DKD is a clinica		ed by reduced e	GFR, the presence le 1 from Davies MJ, A abetes Association (Al	e of albuminuria Aroda VR, Collins BS,	et al. Management of Hy	, contraindicated; HF, hea perglycemia in Type 2 Diabetes, y of Diabetes (EASD). ADA Stand	2022. A Consensus Report by the




Comparison of	f GLP-1 Ago	nists	
Agent	Dosing Schedule	Dosing	
Exenatide (Byetta [®])	Discontinued in US		
Exenatide ER (Bydureon [®])	Discontinued in US		
Liraglutide (Victoza [®])	Daily (Inj)	0.6 mg, 1.2 mg, 1.8 mg	
Dulaglutide (Trulicity [®])	Weekly (Inj)	0.75 mg, 1.5 mg, 3 mg, 4.5 mg	
Lixisenatide (Adlyxin [®])	Daily (Inj)	10 mcg, 20 mcg	
Semaglutide (Ozempic [®])	Weekly (Inj)	0.25 mg, 0.5 mg, 1 mg, 2 mg	
Semaglutide (Rybelsus [®])	Daily (PO)	3mg , 7mg, 14 mg	
GERIATRIC PHARMACIST 2024. Adlyxin insert]. Bags	[package insert]. Bridgewater, NJ: Sanofi; 2024	k; 2024. Ozempic [package insert]. Bagsvaerd, Denmark: Novo Nordisk; Trulicity [package insert]. Indianapolis, IN: Eli Lilly; 2024. Victoza [package [package insert]. Wilmington, DE: AstraZeneca; 2024. Byetta [package	Ь

			CV Effect			nal Effects
	glycemia	Change	MACE		Progression of DKD	Dosing/Use Considerations
Very High	No	Loss (very high)	Under investi	gation	Under investigation	 No dose adjustment Increased risk of SE in patients with renal impairment
			etic kidney disease; HF, hearl A, glucagon-like peptide-1 rea			












Comparison	UI JULI-Z II	
Agent	Dosing	Renal Dosing
Canagliflozin (Invokana*)	100-300 mg daily	 eGFR 30-59 mL/min: 100 mg daily eGFR <30 mL/min with urinary albumin >300 mg/day: do not initiate, may continue 100 mg daily Cl in dialysis
Dapagliflozin (Farxiga [*])	5-10 mg daily HF: 10 mg daily	 eGFR <25 mL/min: do not initiate, may continue 10 mg daily Cl in dialysis
Empagliflozin (Jardiance*)	10-25 mg daily	 eGFR 20-30 mL/min: do not initiate, may continue 10 mg daily Cl in dialysis
Ertugliflozin (Steglatro [®])	5-15 mg daily	• eGFR < 45 mL/min: NR
Bexagliflozin (Brenzavvy [®])	20 mg daily	• eGFR < 30 mL/min: NR
	e. 2024;47(S1):S1-S308. ACCE/ACE Guidelines a atement-comprehensive-type-2-diabetes-manaj	vailable at: https://pro.aace.com/clinical-guidance/2023- gement-algorithm. Accessed 1/10/24













Comparison of DPP-4 Inhibitors

Agent	Dosing	Renal Dosing	
Alogliptin (Nesina [®])	25 mg daily	 eGFR 30-60 mL/min: 12.5 mg daily eGFR <30 mL/min: 6.25 mg daily 	
Linagliptin (Tradjenta®)	5 mg daily	No dose adjustment	
Sitagliptin (Januvia®)	100 mg daily	 eGFR 30-45 mL/min: 50 mg daily eGFR <30 mL/min: 25 mg daily 	
Saxagliptin (Onglyza®)	2.5 - 5 mg daily	• eGFR <45 mL/min: 2.5 mg daily	
• •	2.5 - 5 mg daily	 eGFR <45 mL/min: 2.5 mg daily 	
GERIATRIC PHARMACIS	īτ	II, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the	










Insulin	PK Properties ^a	Administration	Initial Dose/Titration	
Glargine U-100	Onset: 3-4 hrs Duration: 24 hrs			
Glargine U-300	Onset: 6 hrs Duration: 24 hrs	Once daily or twice daily	Initial dose: 10-20 units or 0.1- 0.2 units/kg a day Titration: increase 2 units every 3 days; slower titration for	
Detemir (discontinuing 2024)	Onset: 1-2 hrs Duration: 14-24 hrs			
Degludec	Onset: 1-2 hrs Duration: >40 hrs	Once daily	degludec	
^a Long-acting insulins	have no peak; PK, p	harmacokinetic; min, minu	tes; hrs, hours	




Insulin	PK Properties	Administration	Initial Dose/Titration
Lispro		15 min before or immediately after meal	
Lispro-aabc	Onset: 5-15 min	At start of or within 20 min after starting meal	Initial: 4 units or 10% of the basal insulin dose
Glulisine	Peak: 45-75 min Duration: 3-5 hrs	15 min before or within 20 min after starting meal	Titration: 1-2 units or 10-15 %
Aspart		5-10 min before meal	of dose twice weekly
Aspart ("faster acting")		At start of or within 20 min after starting meal	
Inhaled Insulin	Onset: <15 min Peak: 50 min	At start of meal ^a	Initial: 4 units
	Duration: 2-3 hrs		Titration: 4 units twice weekly


Short-acting and Intermediate-acting Concentrated


Insulin	PK Properties	Administration	Initial Dose/Titration
U-500 regular	Onset: 30 min Peak: 4-8 hrs Duration: 13-24 hrs	Two times daily (60% before breakfast and 40% before supper) Or Three times daily (40% before breakfast, 30% before lunch and supper)	Discontinue all other insulins Initial dose: 80% of the TDD of previous insulin regimen (round down to nearest 5 units) Titration: 5-15% rounded to nearest 5 units
PK, pharmacokineti	c; min, minutes; hrs,	hours; TDD, total daily dose	2
GERIATRIC PHARMACIST BOOT C☆MP	Trujiloo J, Haines S. Diabo	tes mellitis. In: كابَاته مال Yee GC, Posey LM, et al. Pharmacott الجال: 2023: chap 91. Accessed January 24, 2025. <u>https://access</u>	nerapy: A Pathophysiologic


Insulin	PK Properties ^a	Administration	Initial Dose/Titration
NPH/regular 70/30	Onset: 30-60 min Duration: 10-16 hrs	Twice daily 30-45 min before breakfast and supper	Insulin naïve: 0.3 units/kg/day
Lispro 50/50	Onset: 15-30 min Duration: 14-24 hrs	Twice daily 15 min before	or 10 units/day in divided doses
Lispro 75/25	Onset: 5-15 min Duration: 10-16 hrs	breakfast and supper	Converting from other insulin therapy: Current TDD in divided doses
Aspart 70/30	Onset: 10-20 min Duration: 18-24 hrs	Twice daily 15 min before or after breakfast and supper	Titration: individualized
Premixed insulin has du	al peaks; PK, pharmacok	kinetic; min, minutes; hrs, hours; T	DD, total daily dose


Insulin	PK Properties	Administration	Initial Dose/Titration
Glargine/lixisenatide Soliqua®	Refer to	Once daily within 60 min of breakfast	Insulin naïve or current basal insulin dose < 30 units: 15 units Current basal insulin dose ≥ 30 units: 30 units Titration: 2-4 units once weekly Max dose: 60 units
Degludec/liraglutide Xultophy®	individual agents	Once daily with or without food	Insulin naïve or GLP-1 RA naive: 10 units Currently taking basal insulin or GLP-1 RA: 16 units Titration: increase 2 units twice weekly Max dose: 50 units




















Medication Options	Agent	Equivalent Dosing	Pearls
 T₃ Peaks 2-4 hrs T ½ < 1 day Higher risk of thyrotoxicosis 	Liothyronine (T ₃)	25 mcg	 Rapid acting (t_{1/2} ~1 day) Multiple daily dosing Peaks/troughs Avoid in older adults
T ₄ • Peaks 2-4 hrs	Desiccated <i>porcine</i> thyroid (T ₃ >T ₄)	1 grain/60 mg	 Mixed t_{1/2} Inexpensive Thyrotoxicosis risk Avoid in older adults
 T ½ ~ 7 days Requires conversion of T₄ to T₃ Missed doses have less clinical impact 	Levothyroxine (T ₄)	100 mcg	 Long acting (t_{1/2} ~7 days) Stable


Drug Inte	ractions	 Other Considerations: Some AEDs and rifampin may increase clearance Amiodarone therapy and selenium deficiency ma block peripheral conversion 	ıγ	
Protein binding change	es → metabolic ac	livity		
		ogen, estrogen agonist/antagonist, methadone, 5-FU r disease, HIV		
(↑ free concentration/activity) (i.e., p		costeroids, androgens, furosemide, salicylates, AEDs phenytoin) e illness		
Absorption \rightarrow admini	stration, impaired	absorption		
Conditions	Celiac disease, chronic diarrhea, GI bypass surgery			
Interactions	Minerals, BAS, fi (empty stomach	iber supplements, acid suppression therapy, foods n preferred)		
T %, half life; 5-FU, fluorouracil; AEDs, an	arber JR, Cobin RH, Gharib H, et al. Clinical practice gu	Questrants delines for hypothyriodism in adults: ATA and AACE gudelines. Endoce Prazt. 2012;18:988-1028. Kane MP, Ma et al. eds., "harmacaberary. A Pathophyriologic Approach. 12 ^{an} ed. New York. MY. McGraw-Hill, 2023.	bps:	













Hypothyroidism: Clinical Pearls


- Keep your radar up!
- Patient-specific decision to treat subclinical symptoms
- Levothyroxine preferred!
- MULTIPLE drug-drug and drug-disease interactions
- Monitor signs/symptoms of hypothyroidism and over-treatment


GERIATRIC PHARMACIST BOOT C MP


53





















Country: US (Caucasian)	Name/ID:	 Determine DXA Treatment naive 		
Questionnaire:		10. Secondary osteoporosis	⊙No ⊃Yes	
1. Age (between 40 and 90 years) or Age: Date of Birth:	Date of Birth	11. Alcohol 3 or more units/day	⊙No ⊃Yes	Underestimat
60 Y: M:	D:	12. Femoral neck BMD (g/cm ²)		future fractur
2. Sex	Male 💿 Female	Select BMD \$		
3. Weight (kg)	75	Clear Calculate		
4. Height (cm)	160			
5. Previous Fracture	ONO ○Yes	BMI: 29.3 The ten year probability of fracture (%)		
6. Parent Fractured Hip	💿 No 🗌 Yes	without BMD		
7. Current Smoking	💿 No 🗌 Yes	Major osteoporotic	6.8	
8. Glucocorticoids	⊙No ⊃Yes	Hip Fracture	0.5	
9. Rheumatoid arthritis	⊙No ⊖Yes			










Carbonate (40% elemental)	, Citrate (21% elemental), Gluconate (9% elemental)
Effect	Increase BMD (mostly with vitamin D)
Dosing & Formulations	Women 19-50 years old, men 19-70 years old: 1,000 mg/day Women ≥ 51 years old, men ≥ 71 years old: 1,200 mg/day < 600 elemental per dose (500 – 600 mg twice daily)
Considerations	 ↑ elemental Ca = ↑ Constipation Kidney stones Dietary sources preferred QS dietary intake (average 600 mg/day) OP patients are high bone risk—Ca benefit outweighs CV risk







	Vitamin D	25(OH)-Vitamin D Assessment Deficient: < 20 ng/mL Insufficient: < 30 ng/mL No level? Supplement	
-	Vitamin D: Cholecalci	ferol (D ₃) , Ergocalciferol (D ₂)	
	Effect	Enhance calcium absorption Helps osteoporosis drugs work better	
	Considerations	Correct deficiencies and insufficiencies Maintain sufficiency Obesity, malabsorption, AEDs, darker skin tones may require higher doses Long-term doses > 4,000 IU can lead to Vit D toxicity	
-		ho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology I Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(51):1-46.	ьρ











Drug	Prevention	Treatment		
Alendronate (Fosamax [®] , generic)	5 mg PO daily 35 mg PO weekly	10 mg PO daily 70 mg PO weekly (tablet and liquid) 70 mg + D weekly (70 mg alendronate/2,800 IU or 5,600 IU Vit D)		
Ibandronate (Boniva [®] , generic)	2.5 mg PO daily 150 mg PO monthly	2.5 mg PO daily 150 mg PO monthly 3 mg IV every 3 months		
Risedronate (Actonel [®] , Atelvia [®] , generic)	5 mg PO daily 35 mg PO weekly 150 mg PO monthly	5 mg PO daily 35 mg PO weekly 150 mg PO monthly		
Zoledronic acid (Reclast [®] , generic)	5 mg IV every 2 nd year	5 mg IV once yearly		

Bisphospho	nates: alendronate, risedronate, ibandronate, zoledronic acid (ZA)
Indicatio	Post-menopausal prevention/treatment: ALL Steroid-induced prevention: risedronate, ZA Steroid-induced treatment: alendronate, risedronate, ZA Treatment of men: alendronate, risedronate, ZA
Effect	Alendronate, ZA, and risedronate: FRR for vertebral, nonvertebral, and hip Ibandronate: FRR for vertebral fracture only Fracture data available for PO daily and annual IV only Fractures reduced by 6-12 months, plateau 2-5 years FRR, fracture risk reduction
Dosing & Form	Caution in renal impairment, at risk of dehydration, on diuretics or nephrotoxic drugs Ilations Not recommended if eGFR/CrCl < 35 mL/min (alendronate, zoledronic acid) or eGFR/CrCl < 30 (ibandronate, risedronate)
Considerat	Administration instructions (empty stomach, water, upright position, no other drugs) Calcium and Vit D must be WNL before initiation ZA and acute phase reaction (fever, flu-like) Oral formulations: caution if esophageal disease (e.g., strictures) or abnormalities (anatomic or functional), GI malabsorption (e.g., celiac, Crohn's, gastric bypass), inability
Geriatric Phar	to remain upright Difficulty swallowing—effervescent tablet, solution or IV agent Oral tablets must be swallowed whole with 6-8 ounces of water





	and Inhibitor Denosumab (Prolia®, Xgeva®)	
Indications	Treatment of postmenopausal women Treatment in men Steroid-induced osteoporosis	
Effect	FRR for vertebral, nonvertebral, and hip	
Dosing & Formulatior	60 mg SQ in upper arm, thigh, abdomen every 6 months by a healthcare provider No drug holiday recommended—rapid bone loss if discontinued	
Considerations	Must correct Ca and Vit D before initiation Drug of choice in renal impairment Boxed warning for severe hypocalcemia if on dialysis Topical reactions Possible risk for ONJ or atypical femur fracture	
Geriatric pharmacist	ONI = Octaonerrosis of the jaw: FRR = fracture risk reduction Canado PW, Petä SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Biagnosis and Trasment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(5):1-46.	קי

PTH-Ana	logs	Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocr Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Oxteoporosis. Endocr Pract. 2020;26(51):1-	
PTH Analogs: Abalog	paratide (Tym	nlos®), Teriparatide (Forteo®, generic)	
Indications	•	postmenopausal women reatment of men, steroid-induced	
Effect	Fracture Risk F	Reduction for vertebral and nonvertebral only	
Dosing & Formulations		0 mcg SQ to abdomen daily, monitor first dose : 80 mcg SQ daily	
Considerations	(bisphosphona If follow anti-r Must correct (Nausea, ortho Falsely elevate Teriparatide ca Boxed Warnin metastasis	immediately followed by anti-resorptive therapy ate, denosumab) due to rapid bone loss esorptive therapy—lower BMD increases than if prior to therap Ca and Vit D before initiation static hypotension, leg cramps, <u>hyper</u> calcemia ed Ca levels—must check 16 hours after administration an be used beyond 2 years of therapy g: osteosarcoma—avoid if prior radiation to bone or bone ed in patients with hyperparathyroidism	bos.
GERIATRIC PHARMACIST	COST!		ops

Sclerostin Inhibit	or: Romosozumab (Evenity®)
Indications	Treatment of postmenopausal women at high risk for fracture
Effect	Fracture Risk Reduction for vertebral, nonvertebral, and hip
Dosing & Formulations	210 mg once monthly (two consecutive 105 mg injections) in the upper arm, thigh, or abdomen by a healthcare professional 12 month duration—no additional benefit
	 Considered a "rescue drug" for very high fracture risk Must be followed by anti-resorptive therapy (bisphosphonate, denosumab) due to rapid bone loss after discontinuation Can follow bisphosphonate therapy Must correct hypocalcemia prior to use, supplement Ca and Vit D Boxed Warning—increased risk of MI, stroke, and CV death If dose missed, administer ASAP, subsequent dose 1 month later Useful in renal dysfunction, no dose adjustment with eGFR < 30 mL/min/1.73 m² Possible risk for Osteonecrosis of jaw or atypical fracture


Medication	↓Vertebral Fracture (%)	↓Non-vertebral Fracture (%)	↓Hip Frac (%)	ture	个Spine BMD (%)	个Hip BMD (%)
Calcitonin	33				0.7	
Raloxifene	30-42				2.6	2.1
Bazedoxifene +/- estrogens	42				2.2	0.5
Estrogens	33-40	13-27	34		3.5-7	1.7-4.1
Bisphosphonates	41-70	25-39	40-51		4.3-6.7	2.8-6
Denosumab	68	20	40		9.2	6
Teriparitide	65	53			8.6	3.5
Abaloparatide	14*	57			11.2	4.18
Romosozumab	73	19	38		18	4
*Lower vertebral fracture risk population compared to	Fracture Site	Alendronate	Ibandronate	Rised	ronate	Zoledronic Acid
previous studies ph T. DPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. We	Vertebral	Yes	Yes	Y	'es	Yes
Michael Posey+ Table 73- chure and Bone Mineral Density Effects of Oxteoporosis Medications from tal Fracture Trials in Postmenopausal Women. Carracho PM, Petak SM, ley N, et al. American Association of Clinical Endocrinologists and	Non-Vertebral	Yes	No	Y	'es	Yes
arican College of Endocrinology (Linical Practice Guidelines for the grosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 0.26(51):1-46.	Hip	Yes	No	Y	'es	Yes

What Isn't Used and Why?

81

С	alcitonin		
	Calcitonin		-
	Indications	Treatment in women > 5 years past menopause	
	Effect	Fracture Risk Reduction (FRR) for vertebral only	
	Dosing & Formulations	200 IU (1 spray) intranasally daily (alternate) 100 IU SQ/IM daily SQ/IM formulations do not have data for osteoporosis	
	Considerations	Derived from salmon—contraindicated if fish allergy Hypersensitivity—skin testing prior to initiation Nausea Sweating, facial flushing Increased cancer risk—banned in Canada and Europe	_
I GERIAT		YM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology ctice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(51):1-46.	ნი:

Estrogens	
Indications	Prevention in post menopausal women Estrogen only—women with a history of hysterectomy Estrogen and progestin—women with intact uterus
Effect	FRR for vertebral, nonvertebral, and hip Best effect with early replacement
Dosing & Formulations	Numerous products include tablets and transdermal patches
Considerations	↓ Colon cancer risk ↑ Fatal and nonfatal MI , stroke, VTE, breast cancer



bazedoxifene +/- conjug	ated estrogens (Duavee®)
Indications	Post menopausal prevention in women who <u>have not</u> had a hysterectomy
Effect	FRR for vertebral only
Dosing & Formulations	Duavee [®] 1 tablet PO daily
Considerations	Cardiovascular: ↑ VTE Stroke risk in women 70+: not recommended Increased risk of endometrial cancer Potential risk for dementia Do not combine with other estrogen products



bps.

Osteoporosis: Clinical Pearls

- Modify risk factors EARLY
- Importance of patient-specific factors in determining the best treatment and duration
- Dietary calcium > supplement
- Vitamin D importance
- Concomitant therapy is not recommended (exception: raloxifene and breast cancer reduction)
- Upon discontinuation of an anabolic agent, therapy with an anti-resorptive agent is recommended
- Switching from bisphosphonate to an anabolic agent can be done
- Switching from denosumab to an anabolic agent is NOT recommended due to attenuation of effect or bone loss

GeRIATRIC PHARMACIST dc, discontinuation

